GEN Exclusives

More »

GEN Poll

More »
Mar 01, 2012

Roche’s Ploy for Illumina

A day after Roche went public with its $5.7 billion offer for Illumina, on January 26, Illumina placed a poison pill shareholder rights plan in place. Roche responded by nominating a slate of directors for election to Ilumina’s board. On February 7, Illumina issued a formal rejection to Roche, characterizing the offer as “grossly inadequate.” On February 14, a group of Illumina shareholders filed a putative class action against Illumina alleging that its directors breached their fiduciary duties and did not get the best price. Roche has also told Illumina that sales may not expand as quickly as Illumina thinks. Additionally, Roche can certainly hang in for the long run when it goes after a company, as was the case with Ventana and Genentech. How do you think things will end?

Do you expect Roche to eventually win over Illumina and acquire the company?

Yes
 
  67.4%
No
 
  23.5%
Undecided
 
  9.1%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?